Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 3

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 3
---
 pledgees, assignees, donees, transferees or their respective successors-in-interest, from time to time may offer and sell through
public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices
the shares held by them directly or through underwriters, agents or broker-dealers on terms to be determined at the time of sale, as described
in more detail in this prospectus. See “Plan of Distribution” beginning on page 83 of this prospectus for more information
about how the Selling Stockholders may sell their respective shares of Common Stock. The Selling Stockholders may be deemed “underwriters”
within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended.

We have agreed to bear all of the expenses in connection
with the registration of the Common Warrant Shares pursuant to this prospectus. The Selling Stockholders will pay or assume all commissions,
discounts, fees of underwriters, agents, selling brokers or dealer managers and similar expenses, if any, attributable to their respective
sales of the shares of Common Stock.

Our Common Stock is listed on the Nasdaq Capital Market
under the symbol “BIAF”. Our Tradeable Warrants are listed on the Nasdaq Capital Market under the symbol “BIAFW”.
On April 9, 2025, the last reported sale price of (i) our Common Stock on Nasdaq was $0.63 per share, and (ii) our Tradeable Warrants
on Nasdaq was $0.14 per Tradeable Warrant. There is no established public trading market for any of the Common Warrants and we do not
expect a market to develop.

Investing in our securities involves risks. You should review carefully the risks and uncertainties described under the heading “ Risk Factors” contained in this prospectus, as described beginning on page 8 of this prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is not permitted.

<div align='center'>The date of this prospectus is ,
2025

TABLE OF CONTENTS</div>

| ABOUT THIS PROSPECTUS                                                                  |  ii |
| PROSPECTUS SUMMARY                                                                     |   1 |
| THE OFFERING                                                                           |   5 |
| CA